Brokerages Set Neurogene Inc. (NASDAQ:NGNE) Price Target at $51.00

Shares of Neurogene Inc. (NASDAQ:NGNEGet Free Report) have been assigned an average rating of “Buy” from the nine analysts that are presently covering the stock, Marketbeat.com reports. Eight analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $51.00.

Several equities research analysts have issued reports on the stock. Baird R W raised shares of Neurogene to a “strong-buy” rating in a research report on Tuesday, June 11th. Robert W. Baird began coverage on Neurogene in a research note on Tuesday, June 11th. They issued an “outperform” rating and a $54.00 price objective on the stock. BMO Capital Markets started coverage on Neurogene in a report on Thursday, June 27th. They set an “outperform” rating and a $65.00 price objective on the stock. Finally, HC Wainwright lowered their target price on Neurogene from $51.00 to $49.00 and set a “buy” rating for the company in a report on Monday, August 12th.

Read Our Latest Research Report on Neurogene

Hedge Funds Weigh In On Neurogene

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Quest Partners LLC acquired a new position in shares of Neurogene during the second quarter worth $55,000. SG Americas Securities LLC acquired a new position in Neurogene during the 1st quarter valued at about $120,000. Baker BROS. Advisors LP increased its position in Neurogene by 0.6% during the 1st quarter. Baker BROS. Advisors LP now owns 456,015 shares of the company’s stock valued at $23,211,000 after buying an additional 2,499 shares in the last quarter. Privium Fund Management UK Ltd purchased a new stake in Neurogene in the first quarter valued at about $274,000. Finally, Marshall Wace LLP boosted its holdings in Neurogene by 37.2% in the second quarter. Marshall Wace LLP now owns 41,447 shares of the company’s stock worth $1,508,000 after acquiring an additional 11,229 shares in the last quarter. Hedge funds and other institutional investors own 52.37% of the company’s stock.

Neurogene Trading Up 4.5 %

Shares of NASDAQ NGNE opened at $41.75 on Friday. Neurogene has a fifty-two week low of $12.49 and a fifty-two week high of $53.00. The business’s 50 day moving average price is $38.10 and its 200-day moving average price is $37.75.

Neurogene (NASDAQ:NGNEGet Free Report) last released its earnings results on Friday, August 9th. The company reported ($1.09) earnings per share for the quarter, missing the consensus estimate of ($1.02) by ($0.07). The firm had revenue of $0.93 million during the quarter. Analysts forecast that Neurogene will post -4.47 earnings per share for the current year.

Neurogene Company Profile

(Get Free Report

Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.

Featured Stories

Analyst Recommendations for Neurogene (NASDAQ:NGNE)

Receive News & Ratings for Neurogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurogene and related companies with MarketBeat.com's FREE daily email newsletter.